Doctors and researchers worry that FDA-related wagers on Kalshi and Polymarket could compromise drug development studies and erode public trust in the process
On the betting websites Kalshi and Polymarket, people can now wager on whether the Food and Drug Administration will decide this year …
Context & Ripple Effects
Kalshi’s biotech pilot for late-stage trial and regulatory outcomes moved prediction markets directly into drug-development milestones. The new concerns focus on whether turning FDA decisions into tradable events changes incentives around information and study conduct.
The issue arrives as platforms have already considered workplace disclosures for bets tied to material nonpublic information and as companies weigh limits on employee participation. That makes clinical and regulatory markets a sharper test of whether existing safeguards fit high-stakes health decisions.
First-order effects
- Researchers, clinicians and trial participants face a new perceived conflict around studies and FDA decisions when those outcomes can be wagered on, potentially weakening confidence in the process even absent evidence of misconduct.
- Kalshi and Polymarket face greater scrutiny over how their FDA-related markets are designed, monitored and promoted, particularly where nonpublic trial or regulatory information could affect trading.
Second-order effects
- Drug companies, research organizations and their employees may need clearer policies on trading in markets tied to their studies or regulatory interactions, extending the compliance questions already emerging around confidential information.
- Platforms may be pressed to tighten participant screening, market rules and surveillance for health-related contracts; failure to do so could invite more attention from regulators and institutional partners.
Third-order effects
- If prediction markets continue expanding into regulated scientific milestones, platform legitimacy will increasingly depend on governance that distinguishes public-information forecasting from markets vulnerable to insider access or perceived manipulation.
- The episode points to a broader boundary-setting contest: sensitive public-interest decisions may become a limiting case for prediction-market growth, with trust and market integrity—not trading demand alone—shaping which categories endure.
The trend: Prediction markets are moving from broad public events into specialized, information-sensitive domains where compliance controls and institutional trust become central to expansion.